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Pharmacokinetics and effects on plasma retinol
concentrations of 13-cis-retinoic acid in melanoma
patients
F Formelli, E Cavadini, L Mascheroni, F Belli and N Cascinelli
Isituto Nazionale per lo Studio e la Cura dei Tumori, via Venezian 1, 20133 Milan, Italy
Summary The pharmacokinetics of 13-cis-retinoic acid (13cisRA) and its effects on retinol plasma levels were investigated after the first and
the last doses in melanoma patients, who participated in a study run to assess tolerance over a long period of a treatment schedule of
13cisRA associated with recombinant interferon cu2a (rlFN-ac2a). Melanoma patients with regional node metastases after radical surgery were
randomized to be treated for 3 months with rlFN-ca2a, 3 x 106 IU s.c. every other day, associated with oral 13cisRA at doses of 20 mg day-'
(five patients) or 40 mg every other day (seven patients). Maximum 13cisRA blood concentrations usually occurred 4 h after drug
administration, with average values of 406 and 633 ng ml-' (i.e. 1.3 and 2.1 gM) after the 20 and 40 mg dose respectively. The average half-
life (t1,2) was approximately 30 h. The maximum concentration, the t,12 and the area under the concentration-time curves from 0 to 48 h
(AUCOQ48) of 13cisRA did not change after multiple dosing, whereas the AUCO48 of its major blood metabolite, 4-oxo-13-cis-retinoic acid,
increased. Immediately after 13cisRA treatment, retinol plasma levels started to decline and they reached the lowest values (approximately
20% reduction) shortly after the time of maximum 13cisRA concentrations (i.e. 4-12 h after drug intake). Afterwards, values returned to
baseline. The amount of retinol reduction in time was correlated with 13cisRA maximum concentrations.
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Metastatic melanoma generally shows a poor response to treat-
ment. Chemotherapy regimens achieve a 15-20% response rate,
with rare (2-5%) complete responses (Sheridan and Hancock,
1992). Among the biological therapeutic agents tested thus far, the
most effective is interferon (IFN)-a2a, which determines response
rates varying from 11% to 38% (Sheridan and Hancock, 1992).
Recent reports have shown the effects of retinoids as anti-cancer
agents (Hong and Itri, 1994). Enhanced antiproliferative effects
have been reported when IFN was combined with retinoids in
different tumour cell lines, including melanoma (Marth et al,
1993; Lotan et al, 1995; Schaber et al, 1994). The same association
was found to induce response rates similar or even superior to
polychemotherapy in metastatic squamous cell carcinoma of the
skin and the cervix (Lippman et al, 1992a,b). Recently, the combi-
nation of oral 13-cis-retinoic acid (13cisRA), at the dose of
60 mg day-' with s.c. injection of IFN-ct2a at the daily dose of
6 x 106 IU 5 days per weekfor6 months, has been shown to induce
an overall response rate of 30% with 12% complete response in
patients with disseminated malignant melanoma (Fierlbeck et al,
1995). In another study in metastatic malignant melanoma
patients, with 13cisRA at the higher dose of 1 mg kg-' day-' asso-
ciated with a lower dose of IFN-a2a (3 x 106 IU day-'), the total
response rate was 20% (Triozzi et al, 1996); dose reduction
because of toxicity was necessary in 14 out of 25 patients. A
randomized study ofadjuvant recombinant IFN-x2a, to be admin-
istered for a long period of time, was carried out in melanoma
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patients with radical lymph node dissection (Cascinelli et al,
1994). Preliminary analysis ofthe results of the study showed that
IFN a2a, at the dose of3 x 106 IU s.c. 3 times per week for 3 years,
increased disease-free survival compared with patients who
received surgery alone (Cascinelli et al, 1994). With the aim of
testing the effectiveness ofthe association of 13cisRA to rIFN-ac2a
after radical surgery in melanoma patients with node metastases, a
study was carried out to choose the dose of 13cisRA that could be
potentially administered together with IFN-a2a for a long period
of time. A tolerability trial was therefore designed to assess the
toxicity of the association of 13cisRA at the doses of 20 mg day-'
or 40 mg every 2 days, to IFN-a2a, at the dose of 3 x 106 IU s.c.
The results ofthe trial will be published in a separate paper.
As limited information is available on the pharmacokinetics and
metabolism of 13cisRA in cancerpatients, the purpose ofthe study
was to evaluate, in patients participating in the trial, the pharmaco-
kinetics of 13cisRA. Moreover, the effects of 13cisRA on endoge-
nous vitamin A (retinol) were evaluated, as few and contrasting
results have been reported (Goodman et al, 1982; Berni et al,
1993; Collins et al, 1994; Sass et al, 1995).
PATIENTS AND METHODS
Drugs, patients and protocol
Isotretinoin or 13cisRA, administered as 20-mg capsules, and
rIFN-a2a, as 3 x 106 IU vials, were supplied by Hoffman La
Roche (Basle, Switzerland). Pharmacokinetics studies were
performed in 14 out of 30 patients participating in the tolerability
study of rIFN-ax2a associated with 13cisRA, whose protocol was
approved by the ethics committee ofthe Istituto Nazionale Tumori
(Milan, Italy). Subjects were melanoma patients with regional
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Table 1 Patient characteristics
Patient Age Sex Dose Height Weight
number (years) (cm) (kg)
3 45 F 20 mg day-1 170 94
5 51 F 20 mg day-' 163 61
9 46 M 20 mg day-1 170 62
26 49 M 20 mg day-' 180 92
27 52 M 20 mg day-' 179 54
2 60 F 40 mg e.o.d.a 167 75
13 38 F 40 mg e.o.d. 160 57
14 35 F 40 mg e.o.d. 174 80
4 59 M 40 mg e.o.d. 183 87
6 40 M 40 mg e.o.d. 182 74
8 46 M 40 mg e.o.d. 165 54
10 38 M 40 mg e.o.d. 175 85
18 69 M 1 mg kg-' day-' 181 90
19 58 M 1 mg kg-1 day-1 175 73
ae.o.d., every other day
node metastases who had been submitted to radical surgery during
the period April 1995 to April 1996 and who had histologically
proven metastatic lymph nodes. Patients were selected for phar-
macokinetics studies on the basis ofacceptance to be hospitalized
for serial blood sampling. Written informed consent was obtained
from all the patients before drug treatments and pharmacokinetics
evaluation. Patients were randomized to receive rIFN-a2a,
3 x 106 IU s.c. three times per week, plus oral 13cisRA,
20 mg day-' six times per week, or40 mg every 2 days three times
per week (on alternate days vs rIFN-a2a). The last two patients
received 13cisRA at the dose of 1 mg kg-1 day-1 six times per
week. This last schedule was tested to evaluate potential toxicity
because of the high 13cisRA dosage usually used in the treatment
of dermatological disease. Distribution of dosage in different
patients followed a randomized criteria (Table 1). Individual char-
acteristics of the patients are presented in Table 1. Treatment
started 30-35 days after surgery and lasted for 3 months or until
onset ofmajor toxicity or recurrent disease.
Sample collection and analytical procedure
13cisRA was ingested as 20-mg capsules after breakfast, which
consisted of tea and bread. Blood was obtained immediately
before the first drug intake (time 0) and at 1, 2, 3, 4, 6, 8, 12, 20,
24, 36 and 48 h, and for some patients at two other intervals up to
72 h. Immediately after the 48-72 h blood sampling, each subject
initiated the 3-month course of dosing, with 13cisRA taken in the
morning and rIFN-ac2a in the evening. Blood samples were also
collected after the last 13cisRA treatment at the same intervals
from drug intake as with the first dose. Blood was collected in
heparinized tubes, which were wrapped in aluminium foil; all
procedures were performed in the dark. After centrifugation,
plasma was kept frozen at-20°C until analysis, but never for more
than 1 week. Concentrations of 13cisRA, 4-oxo-13cisRA and
retinol were detected by high-performance liquid chromatography
(HPLC). Plasma (200 gl) was added to acetonitrile (400 gl),
vortex-mixed, and centrifuged to pellet the precipitated proteins.
The supernatant (100 ,l) was analysed on a Perkin-Elmer Series
2/1 liquid chromatograph fitted with a C,8 (5 jim) reverse-
phase column (125 x 4.6 mm) and a C,8 precolumn (Perkin-
Elmer, Milan, Italy). The mobile phase consisted of acetonitrile-
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Figure 1 13cisRA (@), 4-oxo-13cisRA (O) and retinol (A) plasma
concentrations (ng ml-') in three representative melanoma patients, following
single (left) and multiple (right) administrations of 13cisRA. (A) Patient 3,
20 mg day-'; (B) patient 4, 40 mg every other day; (C) patient 18,
1 mg kg-1 day-1
water-ethanoic acid (75:23:2, v/v/v) delivered at a flow rate of
2 ml min-'. Detection was performed with a Perkin-Elmer LC95
absorbance detector at 340 nm. The chosen wavelength, which is
not the maximum absorption of 13cisRA, 4oxol3cisRA orretinol,
allows good sensitivity for all three retinoids. The presence ofall-
trans retinoic acid (all-transRA) was also assayed. N-(4-etox-
iphenyl)-retinamide was used as internal standard by adding it to
the acetonitrile used to precipitate the proteins. The limits of
detectability were 10 ng ml-' for 13cisRA and retinol, 20 ng ml-
for 4-oxo-13cisRA, and 5 ng ml-' for all-transRA. Intrassay and
interassay reproducibilities were 7.5% and 8.3% respectively. The
reference standards 13cisRA (molecular weight 300.4) and 4-oxo-
13cisRA (molecular weight 314.5) were supplied by Hoffman La
Roche. The internal standard was supplied by the RW Johnson
Pharmaceutical Research Institute (Spring House, PA, USA). All-
trans retinol (molecular weight, 286) and all-transRA (molecular
weight 300.4) standards were obtained from Sigma Chemical
Company (St. Louis, MO, USA).
Data analysis
The elimination half-lives (t1,2) of 13cisRA were determined by
dividing 0.693 by the elimination rate constants (a). The f-values
were calculated by linear regression of the observed blood ln
concentrations from 12 h to the last measuredblood concentrations.
For 4-oxo-13-cisRA, Ps were not calculated because in most cases
no regression of the blood concentrations was observed in the
interval investigated. The areas under the 13cisRA and 4-oxo-
13cisRA concentration-time curves from 0 to 48 h after the first
(AUCO0481st) and multiple (AUC048n) doses were calculated by the
trapezoidal method. Comparison of the pharmacokinetics parame-
ters (Cmax, AUC048 and t,/2) after the first and multiple doses was
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Figure 2 1 3cisRA (0), 4-oxo-1 3cisRA (O) and retinol (A) plasma concentrations (ng ml-) in two representative melanoma patients showing secondary
maximum concentration of isotretinoin
Table 2 Pharmacokinetic parameters of orally administered 13cisRA in melanoma patients with regional node metastases
First dose (I) Repeated dose (n) Ratios
13cisRAa 4oxoRAb 13cisRAa 4oxoRAb AUC-8 AUC AUC
(13cisRA) (4oxoRA) (4oxoRA)
(n) (I) (n)
Patient Dose C AUC (I) t112 AUCO0 (I) C. AUC,_ (n) tV2 AUCO_ (n) AUCO^_ AUC AUC
number (13cisRA) (13cisRA) (13cisRA)
(ng ml-') (.gg h ml-') (h) (tgg h ml-') (ng ml-') (igg h ml-') (h) (gg h ml-') (I) (I) (n)
3 20 mg day-' 680 7.4 43 12.9 227 4.0 75 8.2 0.5 1.7 2.0
5 20 mg day-' 509 4.3 30 6.6 402 3.5 26 15.3 0.8 1.5 4.4
9 20 mg day-' 537 5.7 25 10.7
26 20 mg day-' 134 2.2 25 5.0 131 1.8 29 4.7 0.8 2.3 2.6
27 20 mg day-' 168 3.9 23 4.9 637 9.6 19 22.1 2.5 1.3 2.3
Mean+s.d. 406+242 4.7+1.9 29+8 8.0+3.6 349±222 4.7+3.4 37+25 12.6+7.7 1.1 0.9 1.7±0.4 2.8+1.1
2 40 mg e.o.d.c 215 6.0 n.d. 8.4 303 6.9 54 19.0 1.1 1.4 2.8
13 40mg e.o.d.c 436 8.2 29 12.6 371 8.1 36 28.2 1.0 1.5 3.5
14 40 mg e.o.d.c 362 5.4 50 6.9 922 8.9 27 29.5 1.6 1.3 3.3
4 40mg e.o.d.c 756 8.5 37 14.8 479 5.1 24 13.5 0.6 1.7 2.6
6 40mg e.o.d.c 793 10.9 25 19.3 546 5.1 20 18.4 0.5 1.8 3.6
8 40mg e.o.d.c 1646 7.9 24 22.5 264 3.8 20 14.6 0.5 2.9 3.8
10 40mg e.o.d.c 220 4.1 n.d. 5.8 628 5.3 23 9.5 1.3 1.4 1.8
Mean+s.d. 633±504 7.3±2.3 33±11 12.9±6.4 502±227 6.2±1.8 29±12 19.0±7.5 0.9±0.4 1.7±0.5 3.1 ±0.7
18 1 mg kg-' day-' 418 5.4 32 7.0 349 4.8 36 10.7 0.9 1.3 2.2
19 1 mg kg-' day-' 394 8.5 24 13.9 493 8.4 20 20.8 1.0 1.6 2.5
al 3cisRA, 13-cis-retinoic acid; b4-oxo-RA, 4-oxo-13-cis-retinoic acid; ce.o.d., every other day.
carried out by means of the paired t-test. Regression analysis was RESULTS
also performed on retinol concentrations vs time, and regression
coefficients (b), which represent in this case the amount of retinol 13cisRA pharmacokinetics after the first and repeated
reduction per hour, were evaluated. This analysis was performed on doses
serial retinol levels of each patient from time 0 up to the last time Representative blood concentration-time curves for 13cisRA,
before retinol concentrations began to increase. This time generally 4-oxo-13cisRA and retinol, after the first and repeated oral admin-
corresponded to the same time of 13cisRA Cmax or at maximum to istrations of 20-40 mg and 1 mg kg-', are shown in Figure 1.
1-3 times ofblood collection after that of 13cisRA Cmax. Baseline endogenous 13cisRA plasma levels ranged from 10 to
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Table 3 Effect of 13cisRA treatment on retinol plasma levels in melanoma patients with regional node metastases
Patient Dose Retinol (ng ml-')
number
Baseline Last time Last time of bb
of regression regression (h)
3 20 mg day- 560 406 27 6 -20.30*
5 20 mg day-' 477 362 24 8 -13.64**
9 20 mg day- 661 530 20 12 -16.39**
26 20 mg day' 630 595 6 12 -2.18NS
27 20 mg day-' 478 ND
2 40 mg e.o.d. 518 451 13 4 -17.80*
13 40 mg e.o.d. 562 469 16 12 -10.52**
14 40 mg e.o.d. 270 222 18 6 -7.01*
4 40 mg e.o.d. 660 508 23 4 -33.20*
6 40 mg e.o.d. 698 513 26 6 -26.70**
8 40 mg e.o.d. 714 431 40 6 -36.77*
10 40 mg e.o.d. 654 577 12 8 -8.92*
18 1 mg kg-' day' 783 688 12 12 -10.03**
19 1 mg kg- day' 638 463 27 12 -7.41*
a(Retinol at baseline - retinol at the last time of regression) x 100 - retinol at baseline. bb Regression coefficients of retinol concentrations vs time. *P < 0.05;
**P < 0.01; NS = not significant. ND, not determined.
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Figure 3 Maximum plasma concentrations of isotretinoin (13cisRA Cmax)
and regression coefficients (b) of retinol vs time after the first dose of
13cisRA in melanoma patients. 13cisRA Cma. is reported as ng ml-', and b,
which was negative, is reported as absolute values
26 ng ml-1 in 7 out of 14 patients and they were lower than
10 ng ml', which corresponds to the limit of 13cisRA sensitivity,
in the remaining patients (data not shown). The concentrations of
13cisRA rose rapidly, and maximum blood concentrations (Cmax)
occurred after 4, 3 and 11 h in eight, five and one patient, respec-
tively, with a mean time to peak of4 h (data not shown). 13cisRA
was rapidly metabolized to 4-oxo-13cisRA, and the levels of this
metabolite soon became higher than those of the parent drug. No
patient had detectable levels of all-transRA (limit of sensitivity,
5 ng ml-'). In 4 out of 14 patients, a secondary maximum concen-
tration of 13cisRA was observed, and this occurred shortly after
the first peak, as shown in Figure 2. The single and average phar-
macokinetics parameters after the first and repeated doses are
reported in Table 2. High inter-patient variability was observed.
After the first dose, maximum blood concentrations of 13cisRA
ranged from 168 to 680 ng ml-l with an average value of
406 ng ml' (i.e. 1.35 UM) and from 215 to 1646 ng ml' with an
average value of633 ng ml (i.e. 2.11 giM) after the 20 and 40 mg
doses respectively. The 13cisRA AUCO0A8 increased with the
increase in the dose, with average values of 4.7 and 7.3 ,ug h ml'
after the 20 and 40 mg doses respectively. The elimination
half-lives (t,,2) could not be assessed in two patients because of
lack ofregression of the concentrations in the interval investigated
in one patient and to insufficient times of blood sampling in the
other patient. The half-lives ranged from 23 to 50 h, with average
values of 29 and 33 h after the 20 mg and 40 mg doses respec-
tively. For the above-mentioned pharmacokinetic parameters there
was no statistical difference (t-test) between the 20 and 40 mg
doses. With respect to the 1 mg kg-' dose, in these two patients the
values of Cmax and AUC,0_8 were in the range of those who
received the 40-mg dose, and those ofthe t,,2 were similar to those
found after the other two doses. Three patients (9, 14 and 26)
stopped treatment after 2 months because of recurrent disease,
therefore blood was sampled after the last dose. Blood sampling
was not performed in patient number nine. There was no differ-
ence in the average maximum concentrations, the half-lives and
the AUC048 values after the first and repeated doses. The average
ratio ofAUC,0-8 after repeated doses to AUC0-8 afterthe first dose
was approximately 1. Conversely, the AUC 0-48 of the metabolite
4-oxo-13cisRA increased after repeated doses, and the ratios of
metabolite AUC048 to parent drug AUC,,08 increased from 1.7
after the first dose to 2.8 and 3.1 after repeated doses.
Effect of 13cis RA on retinol plasma concentrations
With respect to the influence of 13cisRA on endogenous retinol,
immediately after 13cisRA dosing, retinol plasma concentrations
started to decrease slightly but progressively, and the lowest
concentrations were reached at the time of 13cisRA Cmax or
slightly later (see Figure 1). Afterwards, retinol concentrations
increased and baseline values were recovered. On average, base-
line retinol levels were reduced by 20% and this occurred in the
range of 4-12 h (Table 3). A similar effect on retinol levels was
observed after multiple dosing (data not shown). Regression
analysis of retinol concentrations vs time (from time 0 to the last
time before retinol concentration started to increase) was
performed (Table 3). All the regression coefficients (b) were
statistically significant except for patient number 26, who had
the lowest 13cisRA peak levels. Regression analysis was not
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performed for patient number 27 because, as a result of blood
haemolysis, the retinol peak was masked in most blood samples.
The plot of the Cma vs the retinol regression coefficients (reported
as absolute values in Figure 3) evidenced a very good correlation
between these two variables (r = 0.85), indicating that the higher
the 13cisRA Cmax the higher the reduction of retinol.
DISCUSSION
This report describes the pharmacokinetics of 13cisRA in
melanoma patients with regional node metastases who had been
submitted to radical surgery, and it also describes the influence of
this retinoid on endogenous retinol plasma levels. Oral 13cisRA
administration at doses of 20 and 40 mg in stage III melanoma
patients resulted in average drug maximum concentrations of 1.3
and 2 gM respectively. Nothing can be said about peaks achievable
with the 1 mg kg-1 dose, as only two patients were studied after
this dose. It is known that gastrointestinal absorption of 13cisRA
(Colbum et al, 1983), as well as that of other retinoids, is influ-
enced by food intake and composition. All the patients analysed in
the study received the 13cisRA dose after a similar light breakfast.
In spite of this, there was up to an eight-fold variation in peak
plasma levels in patients receiving the same dose. This variability
was still evident when peak levels were considered, taking into
account the dose administered on a mg m-2 basis. Peak levels
similar to those achieved in melanoma patients after the 20- and
40-mg doses have been reported after treatment with higher doses
of 13cisRA. Maximum blood concentrations ranged from 98 to
535 ng ml-', with an average value of 262 ng ml1 (i.e. 0.9 tM) in
patients with cystic acne treated with 80 mg of 13cisRA (Brazzell
et al, 1983), and they ranged from 74 to 511 ng ml-l (i.e. from 0.3
to 1.7 gM) in healthy volunteers receiving a 100 mg per dose
(Khoo et al, 1982). In addition, in these two studies food intake
could not account for variability in absorption as the drug was
administered after an overnight fast. Doses even higher, i.e. 3, 4
and 5 mg kg-', have been administered to advanced cancer
patients, and maximum 13cisRA blood concentrations of 2.5 gM
were achieved after the 5 mg kg-' dose (Goodman et al, 1982). In
children with neuroblastoma treated with the maximum tolerated
dose of 160 mg m-2 day-', the average 13cisRA peak levels was
7.4gM (Villablanca et al, 1995). From all these data it is clear that
after administration of the same dose of 13cisRA, there is a
marked variability in maximum drug blood concentrations
(Brazzell et al, 1983; Goodman et al, 1982). This suggests that, if
therapeutic efficacy and/or toxicity were found to be related to
blood levels, monitoring of drug levels might be indicated in
13cisRA clinical trials. With respect to the association between
toxicity and 13cisRA plasma levels, no conclusion can be drawn
from ourdata because the numberofpatients analysed is small and
none ofthe patients developed severe retinoid related side-effects.
Only five of the investigated patients developed mild side-effects,
i.e. dry skin and lips. Even although the results come from
different studies, it seems that in adults, by increasing the dose
from 20 mg (equivalent to approximately 12 mg m-2) to 5 mg kg-'
(equivalent to approximately 185 mg m-2), there is only a
slight increase in average peaks from 1.3 to 2.5 gM. Finally, high
(i.e. 7.5 JM) maximum 13cisRA concentrations can be achieved in
children, and such concentrations are higher than those observed
in adults after similar doses (i.e. 160 mg m-2 in children and
185 mg m-2 in adults). In some cases, we observed a secondary
13cisRA maximum concentration. A similar observation has been
reported in healthy subjects (Khoo et al, 1982) and is consistent
with enterohepatic recycling.
An average half-life of 30 h, was found in melanoma patients.
Similar values were found in advanced cancer patients, in whom
the half-life averaged approximately 25 h (Goodman et al, 1982).
In patients suffering from cystic acne and in patients with various
keratinization disorders, the half-lives were 10 and 16 h respec-
tively (Brazzell et al, 1983), and in male volunteers the half-life
was 20 h (Khoo et al, 1982). The differences between 13cisRA
half-life in cancer and non-cancer patients might be due to differ-
ences in age.
In melanoma patients, the maximum 13cisRA concentrations,
the AUCs and the elimination half-lives of 13cisRA after repeated
treatments were similar on average to those of the first dose.
Conversely, the AUC of the metabolite 4-oxo-13cisRA after
repeated doses was greater than after the first dose. Thus, as
reported in previous studies (Brazzell et al, 1983), the pharmaco-
kinetics of 13cisRA does not change during continuous treatment.
Between the first and the last 13cisRA dose melanoma patients
received IFN-a2a associated with 13cisRA. Although no conclu-
sion can be drawn, no interaction seems to occur on the pharmaco-
kinetics of 13cisRA by its association with IFN-a2a, as the
observed 13cisRA pharmacokinetics was similar to that of
repeated doses of 13cisRA as a single agent (Brazzell et al, 1983).
None of the melanoma patients had detectable levels (i.e.
.5 ng ml-) ofall-transRA before or after treatment. Such findings
are in contrast with previous results in advanced cancer patients
treated with high doses of 13cisRA (3,4 and 5 mg kg-') (Goodman
et al, 1982). In these patients, all-transRA was detected in the
plasma of most patients, and its concentrations varied from 0% to
30% of the 13cisRA concentrations.
Analysis of the influence of 13cisRA on plasma retinol demon-
strated that the retinoid causes a temporary reduction in retinol
concentration. After the doses of 20 and 40 mg, the reduction was
very slight. Baseline values were reduced on average by only 20%.
However, such a reduction was associated with a statistically
significant regression of retinol levels in all the patients except the
one who had the lowest 13cisRA peak levels. The influence of
13cisRA on retinol plasma levels is confirmed by the correlation
found between 13cisRA C and the amount of retinol reduction. max
The results are in agreement with previous observations of
decreased plasma retinol concentration in the rat after treatment
with 13cisRA (Berni et al, 1993; Collins et al, 1994) and with other
retinoids with modifications in the area ofthe retinol hydroxyl end
group, such as all-transRA and fenretinide (4HPR) (Bemi et al,
1993). In rats, although after administration of equimolar doses
13cisRA was slightly less potent than the other retinoids, it caused
a remarkable and dose-dependent reduction in plasma retinol
concentrations (Bemi et al, 1993). Fenretinide (4HPR), which is
less toxic than 13cisRA and is administered at higher doses, causes
a reduction in retinol plasma levels in humans that is proportional
to the dose (Formelli et al, 1989). In breast cancer patients, retinol
levels were reduced by approximately 40% 24 h after 4HPR at the
dose of 200 mg, i.e. a dose five- to ten-fold higher than that of
13cisRA herein investigated. Other authors have reported no
changes in the plasma retinol concentration following 13cisRA
treatment in humans (Goodman et al, 1982; Sass et al, 1995). As in
such studies patients received 13cisRA doses similar (Sass et al,
1995) or higher (Goodman et al, 1982) than those herein investi-
gated, apossible explanation forthe discordance oftheresults is the
time of blood sampling for retinol analysis. As we have shown,
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after 13cisRA treatment, retinol levels progressively decreased,
with the maximum effect occurring shortly after the maximum
13cisRA concentrations. In the previously reported papers
(Goodman et al, 1982; Sass et al, 1995), no indication is given on
the interval between drug intake and retinol assay.
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